Keybanc Maintains Overweight on Absci, Raises Price Target to $20

10/16/2026
Impact: 70
Healthcare

Keybanc analyst Scott Schoenhaus has maintained an Overweight rating on Absci (NASDAQ: ABSI) and raised the price target from $16 to $20. This adjustment reflects a positive outlook for the company in the market.

AI summary, not financial advice

Share: